When multiple myeloma relapses
RESPOND with increasing rates of complete response over time with KRd
KRd cumulative rates of complete response
Deep response increased over the duration of treatment, mainly during time of Kyprolis® treatment (around 18 months) and beyond2
Longer median PFS for patients with CR in the ASPIRE trial2
Deep response (CR or better, vs VGPR or worse) provide your relapsed patients with extra progression-free time2
Kyprolis® has a tolerable safety profile in combination with Rd
*In ASPIRE, cumulative rates of CR or better for KRd and Rd were 31.8% and 9.3%, respectively (descriptive P<0.001).1 Treatment with the KRd regimen for longer than 18 cycles should be based on an individual benefit–risk assessment (limited data on the tolerability/toxicity of Kyprolis® beyond 18 cycles).3 †Safety population: time from treatment start.
Please read the SmPC for full comprehensive safety information
- Dimopoulos MA et al. Presented at the 21st Congress of EHA; 9–12 June 2016; Copenhagen, Denmark. Abstract P275.
- Stewart AK et al. N Engl J Med 2015;372:142–152.
- Kyprolis® (carfilzomib) Summary of Product Characteristics; 2016.